γ-Aminobutyric
acid aminotransferase (GABA-AT) is a pyridoxal
5′-phosphate (PLP)-dependent enzyme that degrades GABA, the
principal inhibitory neurotransmitter in mammalian cells. When the
concentration of GABA falls below a threshold level, convulsions can
occur. Inhibition of GABA-AT raises GABA levels in the brain, which
can terminate seizures as well as have potential therapeutic applications
in treating other neurological disorders, including drug addiction.
Among the analogues that we previously developed, (1S,3S)-3-amino-4-difluoromethylene-1-cyclopentanoic
acid (CPP-115) showed 187 times greater potency than that of vigabatrin,
a known inactivator of GABA-AT and approved drug (Sabril) for the
treatment of infantile spasms and refractory adult epilepsy. Recently,
CPP-115 was shown to have no adverse effects in a Phase I clinical
trial. Here we report a novel inactivation mechanism for CPP-115,
a mechanism-based inactivator that undergoes GABA-AT-catalyzed hydrolysis
of the difluoromethylene group to a carboxylic acid with concomitant
loss of two fluoride ions and coenzyme conversion to pyridoxamine
5′-phosphate (PMP). The partition ratio for CPP-115 with GABA-AT
is about 2000, releasing cyclopentanone-2,4-dicarboxylate (22) and two other precursors of this compound (20 and 21). Time-dependent inactivation occurs by a conformational
change induced by the formation of the aldimine of 4-aminocyclopentane-1,3-dicarboxylic
acid and PMP (20), which disrupts an electrostatic interaction
between Glu270 and Arg445 to form an electrostatic interaction between
Arg445 and the newly formed carboxylate produced by hydrolysis of
the difluoromethylene group in CPP-115, resulting in a noncovalent,
tightly bound complex. This represents a novel mechanism for inactivation
of GABA-AT and a new approach for the design of mechanism-based inactivators
in general.